Concepedia

Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer

Stefano Cavalieri, Federica Perrone, Rosalba Miceli, Paolo A. Ascierto, Laura D. Locati, Cristiana Bergamini, Roberta Granata, Salvatore Alfieri, Carlo Resteghini, Donata Galbiati,

European Journal of Cancer · 2018 · 45 citations · 21 references

DOI

Concepts

References

21

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

, , +6

Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study

Kay Brantsch, Christoph Meisner, Birgitt Schönfisch et al. · The Lancet Oncology · 2008 · 1K citations

, , +9

Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma

Curtis R. Pickering, Jane H. Zhou, J. Jack Lee et al. · Clinical Cancer Research · 2014 · 594 citations · Full text

Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

E. Maubec, Peter Petrow, Isabelle Scheer-Senyarich et al. · Journal of Clinical Oncology · 2011 · 456 citations · Full text

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Mark G. Kris, D. Ross Camidge, Giuseppe Giaccone et al. · Annals of Oncology · 2015 · 323 citations · Full text

, , +10